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doi:10.1016/j.jtcvs.2006.09.042ardiothoracic surgeons owe a debt of gratitude to Bavaria and collea1
for spearheading these exciting clinical investigations into novel endovas-
cular therapies for aneurysm disease from within the specialty of cardio-
horacic surgery. This provides the opportunity for these investigations to be imbued
ith decades2 of collective wisdom from the perspective of cardiothoracic surg
his also provides the opportunity for our specialty to continue leadership in the
reatment of these diseases as technology advances.
The article by Bavaria and colleagues1 represents a large, multicenter compar
ive trial between traditional aortic surgery and endografting for descending thoracic
ortic aneurysms. The study is well conceived and well presented and demonstrates
atisfactory early performance of the endografts. This is very important work, vital
o the advancement of the field, for which the investigators are to be congratulated.
It is extremely important to evaluate endograft therapy of aneurysms in organized
linical trials. Ultimately, randomized trials of thoracic endografts versus open
urgical repair will be required for strongly based conclusions to be drawn.
It is important for medical science to evaluate endografting of aneurysms with
nthusiasm for this new modality but, at the same time, with a grain of skepticism
r at least realism. Multiple reasons to be cautious can be cited.
onceptual Issues
irst, some question the very concept of repair of an expanding cylindrical structure
y means of a graft placed within its lumen. Stents, it is pointed out, were developed
o keep arteries from closing in (as in coronary angioplasty), not to keep them from
xpanding outward. How can a graft placed inside an enlarging aorta and not
ttached to the aorta prevent the inexorable expansion of that aorta? Some say the
raft would have to go outside, not inside, the aorta, a concept that was tried and
ailed many years ago. To control a herd of cattle, the analogy goes, the wooden pen
as to go outside the cows; an internal endograft is like putting the pen inside the
erd. The concern is that the inexorable expansion of the aorta will ultimately leave
he endograft behind, ignoring it, so to speak. Another conceptual issue concerns
ontinued pressurization of the aneurysmal sac by intercostals or lumbar vessels.
et another conceptual issue concerns the surgeon’s understanding that the strength
f the aorta resides in the adventitia, which is not incorporated in any way by the
ndograft.
hort Duration of Follow-up of an Indolent Disease
his line of reasoning leads to the second major concern. Thoracic aortic aneurysm,
lthough ultimately lethal, is an indolent disease. Many years are generally required
rom the time of diagnosis to the time of aneurysm-related death, especially with
mall- to moderate-sized aneurysms (Figure 1).3 To have patients alive at 1 or 2
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Lears (mean follow-up is only 25.8 months in the present
tudy) is not at all reassuring. These patients would proba-
ly still be alive absent any directed therapy whatsoever. As
onger-term follow-up becomes available through the
UROSTAR investigation of endografting for abdominal
igure 1. Indolent nature of thoracic aortic aneurysm. Survival
efore operative repair is shown for different size classes. Note
hat years generally pass before the mortality risk expresses
tself, even for large aneurysms. Source: Coady MA, Rizzo JA,
ammond GL, et al. What is the appropriate size criterion for
esection of thoracic aortic aneurysms? J Thorac Cardiovasc
urg. 1997;113:476-91. Reprinted with permission from Elsevier
nc.
igure 2. Kaplan–Meier graph representing cumulative freedom
rom any endoleak in patients operated on for abdominal aortic
neurysm with endovascular aneurysm repair. Source: Lange C,
eurs LJ, Buth J, et al. Endovascular repair of abdominal aortic
neurysm in octogenarians: an analysis based on EUROSTAR
ata. J Vasc Surg. 2005;42:624-30. Reprinted with permission fromnlsevier Inc.
86 The Journal of Thoracic and Cardiovascular Surgery ● Febrortic aneurysm, this concern literally comes to life, with
ortality and rupture rearing their ugly heads as the aneu-
ysm disease expresses its natural history, even after “suc-
essful” endografting. The EUROSTAR study of endograft-
ng for abdominal aortic aneurysms is much more mature
han corresponding studies of thoracic aortic aneurysms. In
igure 2 it can be noted that endoleak becomes increas
ommon as duration of follow-up is extended.4 It appears
hat nearly half of patients will experience diagnosed en-
oleak as follow-up becomes extended toward the 5-year
oint. In this context we need to keep in mind that the term
ndoleak is itself a euphemism for failure of treatment. It
as been demonstrated that endoleak predicts the need for
urgical conversion, rupture, and death, which in one
UROSTAR publication affected, respectively, 14%, 13%,
nd 27% of patients by 5 years after the procedure among
atients presenting originally with large aneurysms; these
re sobering statistics after endograft therapy.5 Also con-
erning is the emergence of substantial rates of aneurysm-
elated death after endograft therapy when follow-up ex-
ends to 4 years, especially for large aneurysms.6 This is
hown vividly in Figure 3; this figure suggests, in fact
he aneurysm is indeed ignoring the endograft and merely
xpressing its natural tendency to rupture. In recognition of
hese sobering statistics, several major EUROSTAR publi-
ations end with serious cautions about endograft therapy,
alling attention to concerns about the long-term effective-
igure 3. Cumulative freedom from aneurysm-related death. Note
ow attrition of survival in first 3 years of follow-up and rapid
ttrition in fourth year. Gp, Group. Groups represent increasing
nitial aneurysm size: group A, 4.0 to 5.4 cm; group B, 5.5 to 6.4 cm;
roup C, 6.5 cm or larger. Source: Peppelenbosch N, Buth J,
arris PL, et al. Diameter of abdominal aortic aneurysm and
utcome of endovascular aneurysm repair: does size matter? A
eport from EUROSTAR. J Vasc Surg. 2004;39:288-97. Reprinted
ith permission from Elsevier Inc.ess and safety:
uary 2007
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L● “The high incidence of late secondary interventions is
a cause for concern with regard to broad application of
endovascular AAA repair, and emphasizes the need
for lifelong surveillance.”7
● “Continuing need for surveillance for device related
complications remains necessary.”8
● “. . . the durability of this technique is currently un-
known, and continued use of registries should pro-
vide data from long-term follow-up . . . . Only long-
duration studies can tell us whether this type of therapy
really works—whether it prevents aneurysm growth
and rupture and patient death.”9
● “The midterm outcome of large aneurysms after
EVAR was associated with increased rates of aneu-
rysm related death, unrelated death, and rupture . . . .
This finding may justify reappraisal of currently ac-
cepted management strategies.”6
The encyclopedic Health Services Technology Assess-
ent Text of the Guide to Clinical Preventive Services, 3rd
dition, issued the following concluding statement on en-
ografting: “Long-term complications, including AAA rup-
ure . . . may result in significant long-term morbidity and
ortality.”10
In the context of these long-term concerns, the current
tudy should be viewed as only an extended short-term
nvestigation.
Aside from these general issues, some specific points
bout the study by Bavaria and colleagues and its findings
eserve emphasis, so that the results can be taken in the
ppropriate context.
any Patients Lost to Follow-up
ne becomes especially concerned on noting that follow-up
s complete for only 77% of the surgical group and 86% of
he endograft group. How were these patients lost in the
resent computerized era? Was a Social Security Death
ndex survey run on all the names? The study is a very short
ne, with corporate funding. Why couldn’t each and every
atient be accounted for? What if the missing patients are
issing because they are dead? Were that so, that would be
ery, very serious. What if they are missing because they
ad problems and sought care elsewhere? For a compact,
ell-funded study that depends on accurate information, the
ncompleteness of follow-up of this study is concerning;
tated results should be viewed as approximate.
any Exclusions
he host of study exclusions (mycotic aneurysms, unstable
atients, rupture, acute or chronic dissection, and connec-
ive tissue disorder) is extremely broad. Although this
akes for a relatively uniform study group, only the mildest
ubgroups of aneurysm disease are represented. The patients
eing studied are essentially those at the lowest natural risk “
The Journal of Thoracicrom their disease. (In fact, the endograft group was statis-
ically less symptomatic than the surgical group, which is
urther evidence of mild disease in the endograft-treated
atients.) Also, we must remember that descending aneu-
ysms, for reasons that are not clear, do not naturally
upture until they are about 1 cm larger than ascending
neurysms.3 This issue of relatively mild aneurysm dise
n the stented patients compounds the concerns about in-
omplete follow-up and short follow-up; complete long-
erm follow-up will be needed to provide convincing evi-
ence that these patients have benefited above and beyond
he natural behavior of untreated aneurysms.
Multiple other specific issues were raised by the review-
rs of this article:
● How exactly did one endograft patient have an aor-
toesophageal fistula?
● The criterion for postoperative renal failure is espe-
cially harsh (30% increase in creatinine level) and
seems innately biased against surgical intervention,
where small and transient increases in creatinine lev-
els are the rule rather than the exception.
● It is important to emphasize that paraplegia and para-
paresis do occur with endografting. The authors have
done a service by pointing out the high-risk settings
for endograft-related paraplegia.
● Spinal drains were not used routinely in the surgical
group. This is contrary to standard practice and biases
against the surgical group.
● Why could the authors not define a much larger sur-
gical control group, especially in a multi-institutional
study such as this? Historical control subjects were
accepted, making this question even more cogent.
● Indications for treatment are unclear. Were these di-
mensional? Were all saccular aneurysms treated?
● The increase in aneurysm size in 9 patients is con-
cerning.
● According to Table E2, 16.6% of the patients had cancer.
One wonders how endograft therapy of predominantly
low-risk aneurysms in these patients was justified.
Despite these multiple concerns regarding interpretation
f this study, this investigation represents a bold venture
nto new territory with a promising, albeit unproved, less-
nvasive modality of therapy. We are indebted to the inves-
igators for this work. As the authors rightly point out in
heir concluding statements, it is essential that each patient
ho has received endograft therapy be followed vigilantly
or possible deterioration or complications as time passes.
oreover, it is incumbent on our profession not only to
ollow individual patients closely but also to evaluate the
urability of endograft therapy in general with a vigilant
ye. Although the authors argue that a randomized study
omparing surgical intervention and endografting would be
impossible,” this argument is not convincing. We look
and Cardiovascular Surgery ● Volume 133, Number 2 287
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Lorward to longer and more complete follow-up of these
pecific patients and to randomized studies in the future.
The authors of this important study have done ground-
reaking clinical work, forging a very important initial
oray into endograft treatment of thoracic aortic aneurysms
nd the evaluation of its early efficacy.
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